A working end that articulates
A control wheel articulates the tip toward the treatment target under fluoroscopic guidance, as described in Kim et al. (2017). This design feature does not establish better outcomes than fixed-tip devices.
For ASCs & interventional pain practices
Navigable disc decompression for contained herniations.
L’DISQ® is a navigable percutaneous disc decompression system. Its steerable radiofrequency electrode is designed to direct plasma ablation toward a contained cervical or lumbar herniation under fluoroscopic guidance.
For healthcare professionals. Patient selection, technique and anesthesia are determined by the treating physician and the manufacturer’s Instructions for Use.
What L’DISQ is
The cleared indication, in the manufacturer’s words.
“The L’DISQ® is indicated for coagulation and ablation of disc material to treat symptomatic patients with contained herniated discs.”FDA 510(k) K132797 — clearance letter, summary and Indications for Use, July 30, 2014 · Class II, 21 CFR 878.4400 · Applicant: U&I Corporation (Korea)
510(k) clearance is a substantial-equivalence determination, not FDA approval or evidence of superior clinical outcomes. The FDA submission is not a current Instructions for Use document; broader indications on international marketing pages should not be substituted for this US indication.
Navigable tip
A steerable wand designed to approach herniated disc tissue. Lee et al. (2011) studied lumbar use; descriptions of extruded discs in research do not broaden the contained-herniation indication.
Lumbar & cervical
The 2014 FDA summary describes L’DISQ (lumbar), L’DISQ C and C.7 (cervical). Confirm current models and availability with the manufacturer.
Plasma RF
The FDA summary describes 1.0 mm or 0.7 mm plasma electrodes, depending on model, used with an electrosurgical generator. These are electrode dimensions, not electrode spacing.
Single use
The FDA summary identifies the device as single use. Confirm sterility, packaging and compatible components against current product labeling before ordering.
The difference: a tip that steers.
Navigation toward the herniation, rather than a fixed working position.
Plasma ablation & coagulation
The manufacturer’s product overview describes plasma-mediated tissue removal and thermal coagulation. “Nonthermal” or “no neural injury” would be misleading descriptions of the system’s safety.
Assessment before energy delivery
Ha et al. (2024) describe test stimulation, repositioning for radiating pain or muscle contraction, and an awake patient providing feedback. This single-case technique report is not a universal operating protocol or a guarantee against injury.
Device overview, not procedural instructions. Refer to the current Instructions for Use for operating parameters, warnings, contraindications and limitations. Comparative superiority and freedom from thermal or neural injury are not established here.
Patient selection
When conservative care has not been enough.
A potential option for selected patients with symptomatic contained disc herniations — not a universal alternative to surgery.
Published studies considered symptom-correlated MRI findings and persistent pain despite conservative care. Selection criteria differ: the 2011 lumbar study included symptoms lasting at least one month, while the 2024 cervical report’s discussion suggests more than three months and preserved disc height. These are not verified current IFU criteria.
The 2019 cervical study excluded, among other conditions, myelopathy, extruded herniations, infection and instability. This is a study-specific, nonexhaustive list, not the manufacturer’s contraindication list. Progressive neurological symptoms or suspected cord compression require prompt specialist assessment, not a routine demonstration pathway.
The treating physician must assess alternatives and current IFU contraindications. Failure of an injection does not itself establish candidacy, and this is not a universal alternative to surgery or fusion.
Why ASCs are looking at it
Considerations for administrators and physicians.
A new procedure line
Offer a percutaneous option for appropriately selected patients with contained disc herniations.
Training & facility approval
Use requires appropriate physician training and facility credentialing and privileging. Confirm model-specific training requirements with the manufacturer; this overview does not establish operator eligibility.
Minimally invasive
A percutaneous, needle-based approach — not an open surgery. It is not a replacement for fusion in all patients; patient selection is a physician decision.
Supported by DBNP
Exclusive regional supply, in-service support and the same case-level reconciliation we deliver on every order.
How it works
A general overview of the procedure sequence.
- 01
Access
Percutaneous access to the disc under imaging guidance.
- 02
Navigate
The steerable tip is directed toward the herniated portion of the disc.
- 03
Ablate & coagulate
Plasma RF energy coagulates and ablates targeted disc material.
- 04
Recovery
Post-procedure observation, discharge and follow-up are individualized by the treating team and facility.
A needle-based procedure performed under image guidance. Setting, anesthesia and duration vary by patient and clinical team. This overview is general; see the manufacturer’s Instructions for Use and Procedure Technique.
Published evidence
Selected primary reports, not a systematic review. Outcomes are study-specific, not promises of benefit.
Mean VAS pain fell from 7.08 to 1.84 at 24 weeks; ODI from 41.88% to 16.66%. The abstract reports no major complication, but two disc reherniations at one month. This small series had no control group.
Lee et al., Pain Medicine 2011;12:370–376 — primary abstract
80/106 (75.5%) met both criteria at six months: at least 50% pain reduction and at least 40% ODI improvement. Four patients lost to follow-up were counted as unsuccessful. No control group. The report describes transient weakness and a later cauda equina syndrome event, which the authors considered unrelated to the procedure.
In 40 patients (20 L-DISQ, 20 PDCT), mean L-DISQ VAS fell from 7.6 to 3.0 at 12 months. This was not randomized; both groups received active treatment. Cervical muscle spasm occurred. The paper’s spasm counts and percentages are inconsistent, so no precise rate is quoted here.
Ceylan & Aşık, Turkish Journal of Medical Sciences 2019;49:258–264
Reported intradiscal temperature rises did not exceed 13.25 ± 0.84 °C, with surface rises no greater than 1 °C and no histologic thermal damage to surrounding neural tissue in this experiment. Cadaver findings do not establish living-patient safety or absence of thermal injury.
Hong et al., Pain Medicine 2012;13:1000–1003 — primary abstract
A 34-year-old man with a C5–6 contained herniation had VAS improvement from 7 to 0 by six months and NDI from 30 to 3; the authors report maintenance at two years by telephone. One uncontrolled case cannot establish typical benefit, durability or complication rates.
Ha et al., Journal of Orthopaedic Case Reports 2024;14(1):173–177
None of the clinical reports summarized above is a randomized controlled trial. Small samples, selection bias and lack of untreated or sham controls limit interpretation. Outcomes and definitions cannot be compared as interchangeable success rates. Potential risks discussed in the cervical literature include infection, vascular, esophageal or neural injury, hoarseness and cerebrospinal fluid leak; this is not a complete risk list. Refer to the current IFU.
From demonstration to initial cases.
DBNP coordinates the practical support your team needs to evaluate L’DISQ.
See the system firsthand
Request a demonstration, clinical literature, the current IFU and per-case pricing for your facility.
Train your team
DBNP coordinates hands-on training and in-OR clinical support for initial cases. Discuss scheduling, availability and facility requirements with your account manager.
Plan each procedure
Coordinate supply of the single-procedure kit and case-level reconciliation. Ask DBNP about case-by-case coverage navigation; code selection, payer policy and reimbursement require independent confirmation.
Coding is not coverage. CPT 62287 is not presented here as a verified billing recommendation for L’DISQ or for cervical use. CMS NCD 150.11 lists RF/electrothermal intradiscal procedures, including plasma disc decompression/coblation, as noncovered for low-back pain. That Medicare policy does not establish New Jersey PIP or workers’ compensation coverage. No established NJ payer pathway has been verified; confirm current coding, policy, medical necessity and authorization for each case with the payer and billing team. Clearance, a code or authorization alone does not guarantee payment.
Getting started
See what L’DISQ could bring to your practice.
Contact DBNP to schedule a demonstration and discuss clinical literature, training and supply. Exclusive distribution in NY, NJ, PA & CT.
- Demonstration & clinical literature
- Literature & IFU packet
- Per-case pricing & single-procedure kits
- Hands-on training & initial-case support
- Designated account manager
Request accepted for sending.
Microsoft Outlook accepted your inquiry email to DBNP. Inbox delivery is not guaranteed. If you do not hear back, call 845-558-1336.